Role of the XRCC5/XRCC6 dimer in carcinogenesis and pharmacogenomics

Pharmacogenomics. 2011 Apr;12(4):515-34. doi: 10.2217/pgs.10.209.

Abstract

Over the past few decades, the incidence of cancer has rapidly increased all over the world and cancer remains a major threat to public health. It is believed that cancer results from a series of genetic alterations that lead to the progressive disorder of the normal mechanisms controlling cell proliferation, differentiation, death and/or genomic stability. The response of the cell to genetic injury and its ability to maintain genomic stability by means of a variety of DNA repair mechanisms are therefore essential in preventing tumor initiation and progression. From the same viewpoint, the relative role of DNA repair as a biomarker for prognosis, predictor of drug and therapy responses or indeed as a target for novel gene therapy, is very promising. In this article, we have summarized the studies investigating the association between the XRCC5/XRCC6 dimer and the susceptibility to multiple cancers and discuss its role in carcinogenesis and its potential application to anticancer drug discovery.

Publication types

  • Review

MeSH terms

  • Anticarcinogenic Agents / therapeutic use
  • Antigens, Nuclear / genetics
  • Antigens, Nuclear / physiology*
  • Cell Transformation, Neoplastic / genetics*
  • DNA Breaks, Double-Stranded
  • DNA Helicases / genetics*
  • DNA Helicases / physiology*
  • DNA Repair
  • DNA-Binding Proteins / genetics
  • DNA-Binding Proteins / physiology*
  • Drug Resistance, Neoplasm / genetics*
  • Genomic Instability
  • Humans
  • Ku Autoantigen
  • Neoplasms / drug therapy*
  • Neoplasms / genetics*
  • Pharmacogenetics
  • Polymorphism, Genetic
  • Protein Multimerization

Substances

  • Anticarcinogenic Agents
  • Antigens, Nuclear
  • DNA-Binding Proteins
  • DNA Helicases
  • XRCC5 protein, human
  • Xrcc6 protein, human
  • Ku Autoantigen